AtriCure, Inc. - Common Stock (NQ:ATRC)

54.01 +0.33 (+0.61%)

Delayed Quote Updated: 10:37 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

AtriCure CTO Sells 3,657 Shares ↗

September 12, 2026

Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.

Via The Motley Fool

Topics Regulatory Compliance

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

August 25, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth ↗

August 11, 2026

AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product...

Via MarketBeat

AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue ↗

July 23, 2026

Via Chartmill

AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestone ↗

May 05, 2026

Via Chartmill

AtriCure Inc (NASDAQ:ATRC) Stock Surges on Q4 2025 Earnings Beat and Profitability Milestone ↗

February 17, 2026

Via Chartmill

Topics Earnings

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors ↗

August 07, 2026

The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.

Via The Motley Fool

Topics Regulatory Compliance

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It ↗

August 07, 2026

Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.

Via The Motley Fool

Topics Regulatory Compliance

AtriCure to Participate at Upcoming Investor Conferences

July 27, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure Q2 Earnings Call Highlights ↗

July 23, 2026

AtriCure (NASDAQ:ATRC) reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management,...

Via MarketBeat

Topics Earnings

AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript ↗

July 23, 2026

AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you...

Via Benzinga

Topics Earnings

AtriCure Reports Second Quarter 2026 Financial Results

July 23, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure to Announce Second Quarter 2026 Financial Results

July 02, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

May 27, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook ↗

May 12, 2026

AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding...

Via MarketBeat

AtriCure (ATRC) Q1 2026 Earnings Transcript ↗

May 06, 2026

AtriCure (ATRC) Q1 2026 Earnings Transcript

Via The Motley Fool

AtriCure Reports First Quarter 2026 Financial Results

May 05, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference

April 28, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure to Announce First Quarter 2026 Financial Results

April 14, 2026

From AtriCure, Inc.

Via Business Wire

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching? ↗

March 18, 2026

This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns.

Via The Motley Fool

Topics Derivatives Regulatory Compliance

AtriCure to Participate in the Citizens Life Sciences Conference

February 24, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure (ATRC) Q4 2025 Earnings Call Transcript ↗

February 17, 2026

AtriCure (ATRC) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results

February 17, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results

January 27, 2026

From AtriCure, Inc.

Via Business Wire

AI Diagnostics: The End of the High-Cost Imaging Era

January 16, 2026

Issued on behalf of VentriPoint Diagnostics Ltd.

From Equity Insider

Via GlobeNewswire

What's going on in today's pre-market session ↗

January 15, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.